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Abstract 
Designing a targeted and versatile photothermal agent for integration of precise 
diagnosis and effective photothermal treatment of tumors is desirable but remains a 
great challenge. In this study, folic acid ligand conjugated lipid coated polyaniline 
hybrid nanoparticles (FA-Lipid-PANI NPs) were successfully fabricated by a 
distinctive technology. The obtained hybrid FA-Lipid-PANI NPs with small size 
possessed not only significant photoaccoustic (PA) imaging signal but also 
remarkable photothermal effect for tumor treatment. With PA imaging and 
photothermal therapy (PTT), the tumor could be accurately positioned and 
thoroughly eradicated in vivo after intravenous injection of FA-Lipid-PANI NPs. 
This multifunctional nanoparticle could play an important role in facilitating 
simultaneously imaging and PTT to achieve better therapeutic efficacy. 
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1. Introduction 
Photothermal therapy (PTT) using light-absorbing agents to convert the NIR 
light into heat to burn cancer cells has attracted great attention in recent years as a 
promising approach for cancer treatment.[1-3] However, for effective, safe and 
personalized PTT treatment, it is crucial to identify the location and size of the 
tumors before therapy, to monitor the in vivo distribution of photothermal agents 
during therapy and to evaluate effectiveness after therapy with appropriate imaging 
techniques.[4-6] Therefore, imaging-guided PTT is desired for cancer therapy and 
those photothermal agents with dual imaging and therapeutic functions have 
attracted intensive research interests.[7-12] 
Compared with other available medical imaging modalities, photoacoustic (PA) 
imaging is a newly developed noninvasive imaging system, which combines good 
spectral selectivity of laser light with high resolution and deep penetration of 
ultrasound imaging.[13-15] It is necessary to administrate PA imaging contrast agents 
to minimize the attenuation of light intensity and enhance the contrast of images.[16,17] 
Both PA imaging contrast agents and photothermal agents share the common 
attribute of strong absorption in NIR region. Therefore, it is undoubted that PA 
imaging will be the best guidance for PTT in terms of pre-treatment detection, 
intra-treatment monitor and post-treatment assessment, which can be realized by 
using the same photothermal agent. 
Very recently, organic nanoparticles, such as porphysome and conjugated 
polymer nanoparticles based on polyaniline (PANI), polypyrrole (PPy), and 
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poly-(3,4-ethylenedioxythio-phene):poly(4-styrenesulfonate) (PEDOT:PSS) have 
been reported to act as photothermal agents, showing promising cancer ablation 
effect both in vitro and in vivo.[18-25] Among these conjugated polymers, PANI is the 
oldest and potentially most useful conductive polymer due to its outstanding 
physicochemical properties and low cost.[26] Moreover, PANI is non-cytotoxic and 
has been widely used as the PTT agent for photothermal treatment of cancer in vitro 
and in vivo.[27, 28] However, there is still no report about that the PANI nanoparticles 
can be used as PA imaging contrast agents to guide photothermal treatment. 
In this study, we first successfully demonstrated a folic acid ligand conjugated 
Lipid-polyaniline hybrid nanoparticle (FA-Lipid-PANI NP) which could 
simultaneously act as targeted PA and thermal theranostics for cancer diagnosis and 
treatment in living mice. What’s more, we introduced a method of preparing hybrid 
PANI nanoparticles combined emeralidine salt (ES) PANI doped by dodecylbenzene 
sulfonic acid (DBSA) with the phospholipids, which was conceptually distinct from 
other technologies reported up to the present. In order to further improve the cancer 
selectivity, folic acid (FA) as the targeting ligand was conjugated on the surface of 
Lipid-PANI NPs to obtain the FA-Lipid-PANI NPs (Figure 1a and b). Hence, the 
hybrid FA-Lipid-PANI NPs exhibited some unique advantages. (1) Biosafety: 
FA-Lipid-PANI NP was nontoxic and biodegradable by using the biocompatible 
lipids as coating agents for intravenous administration. (2) Tumour targeting: 
FA-Lipid-PANI NPs possesed both passive and active tumor-targeting abilities via 
enhanced permeability and retention (EPR) effect and folic receptor-mediated 
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transcytosis, respectively. (3) Theranostics: FA-Lipid-PANI NPs could be 
simultaneously used as PA imaging contrast agents and photothermal agents for 
tumor theranostics (Figure 1c). 
2. Experimental Section 
Details of the materials used, syntheses, and analysis and characterization 
methods are provided in the Supporting Information.  
3. Results and Discussion 
In our strategy, PANI was synthesized by using anilinium salts protonated by 
hydrochloride (HCl) and ammonium persulfate as an oxidant.[29] The chemical 
oxidative polymerization process was carried out for 6 hours at 4 ℃ and resulted in 
a dark-green precipitate, which was purified by washing with copious amounts of 
deionized water. The synthesized dark-green precipitate was dedoped by sodium 
hydroxide to obtain a polymer powder of emeralidine base (EB) PANI which had the 
purple color. The molecular weight of synthesized EB PANI was 5500 Da, as 
measured by gel permeation chromatograpy (polydispersity index: 1.1). Then, the 
synthesized EB PANI was dissolved in chloroform and re-doped by DBSA to obtain 
the ES PANI (dark-green solution) with the long chain alkyl group. When PANI and 
1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC) dissolved chloroform 
solution was evaporated, the obtained film would exhibit a phase-separated 
morphology due to immiscibility between the hydrophobic PANI and the 
hydrophilic polar heads of the phospholipids. Furthermore, the long alkyl tail of the 
phospholipid could be gathered together with the long chain alkyl group of ES PANI. 
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After adding the phospholipids, the phase-separated thin film of ES PANI and 
phospholipids was prepared by evaporating the chloroform. The thin film was 
broken by	ultrasonication after adding water to form Lipid-PANI NPs. The obtained 
NPs were highly water-soluble (Figure 2a) and very stable in the aqueous phase for 
photothermal application (Figure S1 in the Supporting Information). Transmission 
electron microscopy (TEM) images showed that Lipid-PANI NPs had smooth 
surface and spherical shape (Figure 2b), with a diameter size of 120.6 ± 5.2 nm 
(Figure 2c). After the conjugation with FA, there were no significant changes in the 
mean size, polydispersity index (PDI) and zeta potential (Table S1 in the Supporting 
Information). Infrared (IR) spectra of EB PANI，ES PANI, and Lipid-PANI NPs 
evidenced the adulteration of DBSA on the surface of PANI and the existence of 
PANI in the final product (Figure S2 in the Supporting Information). Moreover, the 
absorption properties of EB PANI, ES PANI and Lipid-PANI NPs were further 
investigated by UV-vis-NIR spectroscopy. In the absorption spectra of EB PANI, a 
charge transfer between quinoid and benzenoid rings was observed at 550 nm 
(Figure 2d).[30] When EB PANI was doped with DBSA (transition to ES PANI), the 
main absorption peak of charge transfer between quinoid and benzenoid rings was 
red-shifted as a result of increased electron-delivery efficiency. The π–π* transition 
of ES PANI was analogous to that of EB PANI (550 nm), but charge transfer 
between quinoid and benzenoid rings was observed in the NIR region (750 nm).[25] 
Interestingly, when the ES PANI was prepared as Lipid-PANI NPs with 
phospholipids, the absorption peak of charge transfer was further red-shifted since 
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that the Lipid-PANI NPs exhibited strong absorbance in the NIR region (810nm). 
These results indicated that the Lipid-PANI NPs were well-suited as photothermal 
agent and PA imaing contrast agent for use upon NIR laser irradiation at 810 nm. 
We next investigated the photothermal effect of Lipid-PANI NPs compared 
with pure water. Experimentally, we examined the temperature increase as a function 
of 1 mL Lipid-PANI NPs aqueous solution (PANI, 0.1 mg ml-1) under NIR laser 
irradiation (808 nm, 2 W cm-2) for 5 min. The temperature of each studied group was 
real-time recorded by temperature gauge or IR thermal camera. Following exposure 
to NIR light, the temperature of the Lipid-PANI NPs increased rapidly and reached a 
plateau value of approximately 60℃ within 5 min (Figure 2e). In comparison, the 
temperature of the pure water only increased by roughly 8 ℃. Furthermore, thermal 
images also confirmed the photothermal effect by observing an obvious color change 
from purple (pure water) to yellow (solution of Lipid-PANI NPs). Finally, we 
collected four temperature rising (laser on) and cooling (laser off) curves of the 
Lipid-PANI dispersion with concentration of 0.2 mg mL-1 (Figure 2f). As shown in 
Figure 2f, no significant decrease for the temperature elevation was observed after 
four repeated laser on-and-off cycles. These experimental results indicated that the 
Lipid-PANI NPs with high photothermal conversion efficiency and photostability 
could be used as the photothermal materials. 
To explore the application of Lipid-PANI NPs in biomedicine, we first tested 
their potential toxicity by performing methyl thiazolyl tetrazolium (MTT) assay on 
Hela cells. Encouragingly, no significant cytotoxicity of hybrid Lipid-PANI NPs was 
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observed by Lipid-PANI NPs and FA-Lipid-PANI NPs, even the concentration 
reached 100 µg mL−1 after incubation for 24 h (Figure 3a).	 The efficacy of 
photothermal therapy was then evaluated by incubating Hela cells with both 
Lipid-PANI NPs and FA-Lipid-PANI NPs following the exposure to 808 nm laser. 
As expected, the viability of cells under laser irradiation was decreased as the 
concentration	 of the NPs increased (Figure 3a). The killing efficacy could reach 
nearly 70% when the FA-Lipid-PANI NPs concentration was 100 µg mL−1. 
However, the cells incubated with Lipid-PANI NPs showed lower killing efficacy 
than FA-Lipid-PANI NPs under the 808 laser irradiation.	 To further investigate 
cellular uptake of these NPs, FITC (fluorescein isothiocyanate)-labeled NPs were 
co-incubated with Hela cells at the same PANI concentration. In addition, to confirm 
the high efficacy of photothermal ablation of cancer cells, the cells were co-stained 
by 4’-6-diamidino-2-phenylindole (DAPI) and propidium iodide (PI). The 
fluorescent images were shown in Figure 3b and c. The cells incubated with 
Lipid-PANI NPs and FA-Lipid-PANI NPs under the laser irradiation showed a large 
amount of apoptosis or necrosis compared with the control group. In the three 
samples, the largest quantity of NPs was uptaken after treated with FITC-labeled 
FA-Lipid-PANI NPs by the mediating of FA ligand, leading to the largest amount of 
apoptosis. In contrast, little PI fluorescence was observed after Hela cells were 
treated with Lipid-PANI NPs alone, indicating that cells were not damaged by 
Lipid-PANI NPs in the absence of NIR irradiation. This was in good agreement with 
the published report that temperature higher than 50 ℃ could evoke irreversible 
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cell damage and necrosis.[21] 
Based on the in vitro results, we next examined the Lipid-PANI NPs for PA 
imaging in vivo. Initially, we investigated the feasibility of Lipid-PANI NPs for in 
vivo PA imaging, in which Hela tumor-bearing Balb/C mice were selected as the 
animal model. Animal experiments were approved by the China Committee for 
Research and Animal Ethics in compliance with the law on experimental animals. 
When the tumors reached approximately 60 mm3, the mice were treated with 
intravenous (i.v.) injections of FA-Lipid-PANI NPs (200 µL, 1 mg mL-1). As shown 
in Figure 4a, compared to pre-injection images, PA signals at 2 h post-injection were 
detected in the superficial area of the tumor, attributing to the accumulation of NPs 
in the blood vessel around the superficial area of the tumor. At 6 h post-injection, PA 
signals induced by FA-Lipid-PANI NPs further increased (Figure 4b). At 24 h 
post-injection, the PA signals decreased slightly while appearing in the whole tumor 
region, indicating the deeply penetration of FA-Lipid-PANI into the inner tumor 
region. 
We further investigated the in vivo therapeutic effect of Lipid-PANI NPs. Three 
groups (five mice per group) of Hela tumor-bearing Balb/C mice were used in our 
experiment. The saline, Lipid-PANI NPs, or FA-Lipid-PANI NPs solutions were 
administered by a single tail intravenous injection, respectively. After 6 h, the 
tumors were irradiated by the NIR laser (808 nm, 2 W cm-2, 5 min). We next 
monitored the temperature changes in those areas of tumors. The whole body 
temperature distribution images of mice induced by NIR laser were investigated 
10	
	
using the IR thermal camera. As shown in Figure 4c, upon the 808 nm laser 
irradiation, the local tumor temperature of the FA-Lipid-PANI NPs injected group 
rapidly increased to approximate 50 ℃, which was high enough to ablate the tumor 
cells. While the temperature of Lipid-PANI NPs treated mice increased to less than 
43 ℃ under the same irradiation condition. For the control group, the tumor 
temperature of saline injected mice exhibited no significant increase (below 37 ℃) 
after laser irradiation. In addition, the tumor sections collected from mice in different 
groups were stained by DAPI and observed by a CLSM to explore the Lipid-PANI 
NPs distribution in tumor site. After treatment with FITC-labeled FA-Lipid-PANI 
NPs, significant fluorescence intensity of FITC was observed in the region of the 
tumor compared to saline and Lipid-PANI NPs treated group (Figure 4d and Figure 
S3 in the Supporting Information). Furthermore, the tumor tissues were collected 
after 1 day for hematoxylin and eosin (H&E) staining	 studies (Figure 4e). In the 
FA-Lipid-PANI NPs plus irradiation group, condensation of chromatins and 
fragmentations of nuclear could be found in the tumor tissues, indicating the 
intensive necrosis or apoptosis of the cancer cells. In comparison, the tumor cells in 
the control groups largely retained their normal morphology with distinctive 
membrane and nuclear structures. Moreover, H&E stained images of main organs of 
FA-Lipid-PANI NPs treated mice (collected 10 d after injection) indicated no 
appreciable abnormality or noticeable organ damage (Figure S4 in the Supporting 
Information). Upon NIR irradiation at 2 W cm-2 for 5 min, the tumors of the mice 
treated with FA-Lipid-PANI NPs shrank during the first four days. On the tenth day, 
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the tumors were completely eliminated, leaving the original tumor site with black 
scars (Figure S5 in the Supporting Information). These results indicated that 
FA-Lipid-PANI NP has great potential to use as a target photothermal agent for 
effective tumor therapy. 
4. Conclusions 
In summary, FA-Lipid-PANI NPs which were prepared from phase-separated 
films of PANI and DPPC by breaking the films with ultra-sonication in water for 
cancer diagnosis and treatment, were reported for the first time. The resulting 
Lipid-PANI-assembled NP could be used as used as the active agents in PA 
imaging-guided PTT. With biocompatible DPPC coating, Lipid-PANI NPs were 
stable in physiological environments and showed little toxicity to Hela cells at all the 
tested concentrations. The cancer cell ablation effect under the NIR laser was 
observed in the in vitro experiments. Moreover, the FA-Lipid-PANI NPs, which 
were prepared by the appropriate surface conjugation with FA ligand, had achieved 
the tumor-targeted PTT effect after systemic administration. The FA-Lipid-PANI 
NPs could thus be used as targeted photothermal agents employing by NIR light. 
Due to the thermosensitive property of DPPC,[31] it was expected that the further 
combination with chemotherapy by loading the therapeutic drugs, might offer great 
opportunities in the development of new cancer therapeutic approaches. Further 
studies were ongoing in our laboratory to realize PA imaging-guided cancer 
thermo-chemo therapy using these photothermal hybrid NPs upon systemic 
administration. 
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Figure captions 
Figure 1. a) A scheme showing the preparation of ES PANI from EB PANI and the 
chemical structure of DPPC. b) Schematic illustration to show the synthesis of 
FA-Lipid-PANI NPs. c) Illustration of the photoacoustic imaging guided 
photothermal therapy using the FA-Lipid-PANI NPs. 
Figure 2. a) Solubility test of Lipid-PANI NPs (left) and ES PANI (right) in 
chloroform (lower phase) and water (upper phase). b)	TEM image of Lipid-PANI 
NPs (scale bar = 0.2 µm). c) Size distribution of Lipid-PANI NPs. d) UV-Vis-NIR 
absorption spectra of Lipid-PANI NPs dispersed in water, ES PANI and EB PANI 
dissolved in chloroform. e) Temperature evolution curves and photothermal images 
of pure water and aqueous solution of Lipid-PANI NPs over a period of 5 min 
following exposure to the NIR laser (808 nm, 2 W cm-2). f) Temperature monitoring 
of a Lipid-PANI aqueous suspension at the concentration of 0.2 mg/mL during for 
successive cycles of an on-and-off laser. 
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Figure 3. a) Cell viability studies by MTT assay for Hela cells after incubation with 
various concentrations of Lipid-PANI NPs and FA-Lipid-PANI NPs with or without 
NIR laser for 24 h, respectively. The data are shown as mean ± standard deviation 
(SD). Error bars are based on at least triplicate measurements; * P < 0.05, ** P < 
0.01. b)	 Confocal fluorescence images of DAPI/ PI stained Hela cells with or 
without FITC-labeled Lipid-PANI NPs incubation after being exposed to the 808 nm 
laser at 2 W cm-2 (scale bar = 25 µm). Blue, red and green colors in the images are 
represented DAPI-stained nuclear fluorescence, PI-stained dead cell fluorescence 
and FITC-labeled Lipid-PANI NPs fluorescence, respectively. c) Confocal 
fluorescence images of DAPI / PI stained Hela cells with and without Lipid-PANI 
NPs incubation after being exposed to the 808 nm laser at 2 W cm-2(scale bar = 100 
µm). Blue and purple colors represented live and dead cells, respectively. 
Figure 4. a) PA images, ultrasound (US) images, and overlaid PA (red) and US 
images (grey) of Hela tumor (region enveloped by yellow dotted line) before and 
after tail vein injection of 200 µL of FA-Lipid-PANI NPs (1 mg ml-1) in living mice 
(excitation wavelength = 808 nm for PA imaging). d) Quantitative analysis of PA 
intensity obtained from Hela tumor images before and after injection with 
FA-Lipid-PANI NPs in living mice (n = 3). c) Photothermal images and the 3D 
temperature distribution of tumor-bearing nude mice that exposed to the NIR laser 
irradiation (808 nm, 2 W cm-2, 5min). b) In vivo distribution of Lipid-PANI NPs and 
FA-Lipid-PANI NPs in nude mice bearing Hela tumors 6 h post treatment. d) 
Histological analysis of Lipid-PANI NPs distribution in tumors post various 
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treatments (scale bar = 50 µm). Blue and green colors in the images are represented 
DAPI-stained nuclear fluorescence and FITC-labeled Lipid-PANI NPs fluorescence, 
respectively. e) H&E-stained tumor slices collected from mice post various 
treatments (scale bar = 25 µm). 
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NIR laser for 24 h, respectively. The data are shown as mean ± standard deviation 
(SD). Error bars are based on at least triplicate measurements; * P < 0.05, ** P < 
0.01. b)	 Confocal fluorescence images of DAPI/ PI stained Hela cells with or 
without FITC-labeled Lipid-PANI NPs incubation after being exposed to the 808 nm 
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Figure 4. a) PA images, ultrasound (US) images, and overlaid PA (red) and US 
images (grey) of Hela tumor (region enveloped by yellow dotted line) before and 
after tail vein injection of 200 µL of FA-Lipid-PANI NPs (1 mg ml-1) in living mice 
(excitation wavelength = 808 nm for PA imaging). b) Quantitative analysis of PA 
intensity obtained from Hela tumor images before and after injection with 
FA-Lipid-PANI NPs in living mice (n = 3). c) Photothermal images and the 3D 
temperature distribution of tumor-bearing nude mice that exposed to the NIR laser 
irradiation (808 nm, 2 W cm-2, 5min). d) Histological analysis of Lipid-PANI NPs 
distribution in tumors post various treatments (scale bar = 50 µm). Blue and green 
colors in the images are represented DAPI-stained nuclear fluorescence and 
FITC-labeled Lipid-PANI NPs fluorescence, respectively. e) H&E-stained tumor 
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slices collected from mice post various treatments (scale bar = 25 µm). 
 
	
 
